Virbac operates in the Pharmaceutical preparations sector. Virbac SA is a France-based veterinarian pharmaceutical company that specializes in the development and production of vaccines and medicines for domestic animals and livestock. The Company's research centers are located in France, Australia, the United States, Mexico and Vietnam. Its development efforts focus mainly on formulating drugs designed to prevent or cure certain animal diseases. Virbac SA's portfolio of products is comprised of Effipro and Fiproline external parasiticides, Canigen, a vaccine against canine distemper, parvovirosis, and canine parinfluenza; EasOtic, an treatment for otitis in dogs, Backhome, an electronic identification chip, and Rilexine, an antibiotic used in skin diseases, among others. The Company has a commercial presence in more than 100 countries worldwide and production sites in seven countries. It operates 27 subsidiaries outside France, including Virbac Sp. z o.o., Interlab SAS, Virbac Mexico SA de CV and Animedica SA, among others. In our complete report available for purchase the company is compared to: China Meheco Corporation, CNIM - Constructions Industrielles de la Mediterranee and Lafuma SA.